Noguchi Mitsuyo, Yokoyama Masatoshi, Watanabe Sumiko, Uchiyama Michiko, Nakao Yoshifumi, Hara Kouichi, Iwasaka Tsuyoshi
Department of Obstetrics and Gynecology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Cancer Lett. 2006 Mar 28;234(2):135-42. doi: 10.1016/j.canlet.2005.03.053.
To investigate the effect of (-)-epigallocatechin gallate (EGCG) on cervical adenocarcinoma, we performed a cell proliferation assay. TRAP assay is used for telomerase activity, flow cytometry analysis and pKi-67 immunofluoroscein staining in cervical adenocarcinoma cell lines (OMC-4, TMCC-1). Our results showed that EGCG inhibited the proliferation assay, TRAP assay for telomerase activity of both cell lines. Although cell apoptosis was induced, we observed that the expression of pKi-67 was suppressed. Our data suggest that EGCG may be effective for the treatment of cervical adenocarcinoma. The mechanisms of the anti-tumor effects were revealed to be the inhibition of telomerase activity, the induction of apoptosis and cell cycle dysregulation.
为研究（-）-表没食子儿茶素没食子酸酯（EGCG）对宫颈腺癌的影响，我们进行了细胞增殖试验。采用端粒重复序列扩增法（TRAP法）检测宫颈腺癌细胞系（OMC-4、TMCC-1）的端粒酶活性，并进行流式细胞术分析和pKi-67免疫荧光染色。我们的结果表明，EGCG抑制了这两种细胞系的增殖试验及TRAP法检测的端粒酶活性。虽然诱导了细胞凋亡，但我们观察到pKi-67的表达受到抑制。我们的数据表明，EGCG可能对宫颈腺癌的治疗有效。抗肿瘤作用机制显示为抑制端粒酶活性、诱导细胞凋亡和细胞周期失调。
